Randomized controlled trial of mineralocorticoid receptor blockade in children with chronic kidney allograft nephropathy

Clinical Journal of the American Society of Nephrology

Volumn 12, Issue 8, 2017, Pages 1291-1300

  Medeiros, Mara ^a   Velásquez Jones, Luis ^a   Hernández, Ana M ^a   Ramón García, Guillermo ^a   Valverde, Saúl ^a   Fuentes, Yolanda ^a   Vargas, Arindal ^a   Patino, Mauricio ^a   Pérez Villalva, Rosalba ^b,c   Ortega Trejo, Juan Antonio ^b,c   Barrera Chimal, Jonatan ^b,c   Bobadilla, Norma A ^b,c  

^a HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CARBONATE; CYSTATIN C; EPLERENONE; HEAT SHOCK PROTEIN 72; KIDNEY INJURY MOLECULE 1; MINERALOCORTICOID ANTAGONIST; PLACEBO; TRANSFORMING GROWTH FACTOR BETA; 8-HYDROXYGUANOSINE; BIOLOGICAL MARKER; GUANOSINE; HAVCR1 PROTEIN, HUMAN; SPIRONOLACTONE;

ADOLESCENT; ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY SURFACE; CHEMILUMINESCENCE IMMUNOASSAY; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC KIDNEY FAILURE; CLINICAL EVALUATION; CONTROLLED STUDY; CREATININE URINE LEVEL; DENSITOMETRY; DNA DAMAGE; ELECTROLYTE BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION AND FOLLOW UP; FEMALE; FIBROSING ALVEOLITIS; GASTROENTERITIS; GLOMERULOSCLEROSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERSTITIAL NEPHRITIS; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; OXIDATIVE STRESS; POST HOC ANALYSIS; PROSPECTIVE STUDY; PROTEINURIA; URINALYSIS; URINARY TRACT INFECTION; YOUNG ADULT; AGE; ALBUMINURIA; ALLOGRAFT; ANALOGS AND DERIVATIVES; BIOPSY; CHILD; DISEASE EXACERBATION; DRUG ADMINISTRATION; DRUG EFFECTS; FIBROSIS; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; KIDNEY; KIDNEY TRANSPLANTATION; METABOLISM; MEXICO; PATHOPHYSIOLOGY; SINGLE BLIND PROCEDURE; TIME FACTOR; TREATMENT OUTCOME; URINE;

ADOLESCENT; AGE FACTORS; ALBUMINURIA; ALLOGRAFTS; BIOMARKERS; BIOPSY; CHILD; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROSIS; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS; GUANOSINE; HEPATITIS A VIRUS CELLULAR RECEPTOR 1; HSP72 HEAT-SHOCK PROTEINS; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MEXICO; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; SPIRONOLACTONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 85026921596     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05300516     Document Type: Article

References (45)

1. Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR: The natural history of chronic allograft nephropathy. N Engl J Med 349: 2326–2333, 2003
2. Haas M: Chronic allograft nephropathy or interstitial fibrosis and tubular atrophy: What is in a name? Curr Opin Nephrol Hypertens 23: 245–250, 2014
3. Stegall MD, Park WD, Larson TS, Gloor JM, Cornell LD, Sethi S, Dean PG, Prieto M, Amer H, Textor S, Schwab T, Cosio FG: The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant 11: 698–707, 2011
4. Viero RM, da Silva MG, dos Santos DC, de Carvalho MF, de Andrade LG: The role of renin-angiotensin system in the chronic allograft nephropathy: An immunohistochemical study. Ren Fail 37: 827–834, 2015
5. Abramowicz D, Wissing KM, Broeders N: Nephrotoxicity of calcineurin inhibitors: New therapeutic approaches. Transplant Proc 32[1A Suppl]: 3S–5S, 2000
6. Bobadilla NA, Gamba G: New insights into the pathophysiology of cyclosporine nephrotoxicity: A role of aldosterone. Am J Physiol Renal Physiol 293: F2–F9, 2007
7. Jaisser F, Farman N: Emerging roles of the mineralocorticoid receptor in pathology: Toward new paradigms in clinical pharmacology. Pharmacol Rev 68: 49–75, 2016
8. Wolf G: Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int 70: 1914–1919, 2006
9. Huang W, Xu C, Kahng KW, Noble NA, Border WA, Huang Y: Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells. Am J Physiol Renal Physiol 294: F1287–F1295, 2008
10. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, Poirier F, Lacolley P, Zannad F, Rossignol P, López-Andrés N: Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 33: 67–75, 2013
11. Vallon V, Wyatt AW, Klingel K, Huang DY, Hussain A, Berchtold S, Friedrich B, Grahammer F, Belaiba RS, Görlach A, Wulff P, Daut J, Dalton ND, Ross J Jr., Flögel U, Schrader J, Osswald H, Kandolf R, Kuhl D, Lang F: SGK1-dependent cardiac CTGF formation and fibrosis following DOCAtreatment. J Mol Med(Berl) 84: 396–404, 2006
12. Irita J, Okura T, Kurata M, Miyoshi K, Fukuoka T, Higaki J: Osteopontin in rat renal fibroblasts: Functional properties and transcriptional regulation by aldosterone. Hypertension 51: 507–513, 2008
13. Kadoya H, Satoh M, Sasaki T, Taniguchi S, Takahashi M, Kashihara N: Excess aldosterone is a critical danger signal for inflammasome activation in the development of renal fibrosis in mice. FASEB J 29: 3899–3910, 2015
14. Yamahara H, Kishimoto N, Nakata M, Okazaki A, Kimura T, Sonomura K, Matsuoka E, Shiotsu Y, Adachi T, Matsubara H, Iwasaka T, Mori Y: Direct aldosterone action as a profibrotic factor via ROS-mediated SGK1 in peritoneal fibroblasts. Kidney Blood Press Res 32: 185–193, 2009
15. Feria I, Pichardo I, Juárez P, Ramírez V, González MA, Uribe N, García-Torres R, López-Casillas F, Gamba G, Bobadilla NA: Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 63: 43–52, 2003
16. Pérez-Rojas JM, Derive S, Blanco JA, Cruz C, Martínezde la Maza L, Gamba G, Bobadilla NA: Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 289: F1020–F1030, 2005
17. Amador CA, Bertocchio JP, Andre-Gregoire G, Placier S, Duong Van Huyen JP, El Moghrabi S, Berger S, Warnock DG, Chatziantoniou C, Jaffe IZ, Rieu P, Jaisser F: Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration. Kidney Int 89:354–362, 2016
18. Mejía-Vilet JM, Ramírez V, Cruz C, Uribe N, Gamba G, Bobadilla NA: Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. Am J Physiol Renal Physiol 293: F78–F86, 2007
19. Sánchez-Pozos K, Barrera-Chimal J, Garzón-Muvdi J, Pérez-Villalva R, Rodríguez-Romo R, Cruz C, Gamba G, Bobadilla NA: Recovery from ischemic acute kidney injury by spironolactone administration. Nephrol Dial Transplant 27: 3160–3169, 2012
20. Barrera-Chimal J, Prince S, Fadel F, El Moghrabi S, Warnock DG, Kolkhof P, Jaisser F: Sulfenic acid modification of endothelin B receptor is responsible for the benefit of a nonsteroidal mineralocorticoid receptor antagonist in renal ischemia. J AmSoc Nephrol 27: 398–404, 2016
21. Pérez-Rojas J, Blanco JA, Cruz C, Trujillo J, Vaidya VS, Uribe N, Bonventre JV, Gamba G, Bobadilla NA: Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 292: F131–F139, 2007
22. Ojeda-Cervantes M, Barrera-Chimal J, Alberú J, Pérez-Villalva R, Morales-Buenrostro LE, Bobadilla NA: Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: A double-blind, randomized pilot study. Am J Nephrol 37: 481–490, 2013
23. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, Halloran PF, Baldwin W, Banfi G, Collins AB, Cosio F, David DS, Drachenberg C, Einecke G, Fogo AB, Gibson IW, Glotz D, Iskandar SS, Kraus E, Lerut E, Mannon RB, Mihatsch M, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Roberts I, Seron D, Smith RN, Valente M: Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 8: 753–760, 2008
24. Zappitelli M, Parvex P, Joseph L, Paradis G, Grey V, Lau S, Bell L: Derivation and validation of cystatin C-based prediction equations for GFR in children. Am J Kidney Dis 48: 221–230, 2006
25. Barrera-Chimal J, Pérez-Villalva R, Cortés-González C, Ojeda-Cervantes M, Gamba G, Morales-Buenrostro LE, Bobadilla NA: Hsp72 is an early and sensitive biomarker to detect acute kidney injury. EMBO Mol Med 3: 5–20, 2011
26. Morales-Buenrostro LE, Salas-Nolasco OI, Barrera-Chimal J, Casas-Aparicio G, Irizar-Santana S, Pérez-Villalva R, Bobadilla NA: Hsp72 is a novel biomarker to predict acute kidney injury in critically ill patients. PLoS One 9: e109407, 2014
27. Ortega-Trejo JA, Pérez-Villalva R, Barrera-Chimal J, Carrillo-Pérez DL, Morales-Buenrostro LE, Gamba G, Flores ME, Bobadilla NA: Heat shock protein 72 (Hsp72) specific induction and temporal stability in urine samples as a reliable biomarker of acute kidney injury (AKI). Biomarkers 20: 453–459, 2015
28. Greene EL, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 98: 1063–1068, 1996
29. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr.: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31: 451–458, 1998
30. Rocha R, Chander PN, Zuckerman A, Stier CT Jr.: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33: 232–237, 1999
31. Amador CA, Barrientos V, Pena J, Herrada AA, González M, Valdés S, Carrasco L, Alzamora R, Figueroa F, Kalergis AM, Michea L: Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. Hypertension 63: 797–803, 2014
32. Piecha G, Koleganova N, Gross ML, Geldyyev A, Adamczak M, Ritz E: Regression of glomerulosclerosis in subtotally nephrec-tomized rats: Effects of monotherapy with losartan, spironolactone, and their combination. Am J Physiol Renal Physiol 295: F137–F144, 2008
33. Barrera-Chimal J, Pérez-Villalva R, Ortega JA, Sánchez A, Rodríguez-Romo R, Durand M, Jaisser F, Bobadilla NA: Mild ischemic injury leads to long-term alterations in the kidney: Amelioration by spironolactone administration. Int J Biol Sci 11: 892–900, 2015
34. Barrera-Chimal J, Pérez-Villalva R, Rodríguez-Romo R, Reyna J, Uribe N, Gamba G, Bobadilla NA: Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury. Kidney Int 83: 93–103, 2013
35. Trachtman H, Weiser AC, Valderrama E, Morgado M, Palmer LS: Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction. J Urol 172: 1590–1594, 2004
36. Chen H, Sun F, Zhong X, Shao Y, Yoshimura A, Liu Y: Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress. Kidney Blood Press Res 37: 557–566, 2013
37. Han SY, Kim CH, Kim HS, Jee YH, Song HK, Lee MH, Han KH, Kim HK, Kang YS, Han JY, Kim YS, Cha DR: Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 17: 1362–1372, 2006
38. Guo C, Martinez-Vasquez D, Mendez GP, Toniolo MF, Yao TM, Oestreicher EM, Kikuchi T, Lapointe N, Pojoga L, Williams GH, Ricchiuti V, Adler GK: Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 147: 5363–5373, 2006
39. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J: Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 13: 189–197, 2007
40. Tsuboi N, Kawamura T, Okonogi H, Ishii T, Hosoya T: The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease. J Renin Angiotensin Aldosterone Syst 13: 113–117, 2012
41. Sengul E, Sahin T, Sevin E, Yilmaz A: Effect of spironolactone on urinary protein excretion in patients with chronic kidney disease. Ren Fail 31: 928–932, 2009
42. Mulatero P, Milan A, Williams TA, Veglio F: Mineralocorticoid receptor blockade in the protection of target organ damage. Cardiovasc Hematol Agents Med Chem 4: 75–91, 2006
43. McManus F, McInnes GT, Connell JM: Drug insight: Eplerenone, a mineralocorticoid-receptor antagonist. Nat Clin Pract Endocrinol Metab 4: 44–52, 2008
44. Bertocchio JP, Barbe C, Lavaud S, Toupance O, Nazeyrollas P, Jaisser F, Rieu P: Safety of eplerenone for kidney-transplant recipients with impaired renal function and receiving cyclosporine A. PLoS One 11: e0153635, 2016
45. Bramlage P, Swift SL, Thoenes M, Minguet J, Ferrero C, Schmieder RE: Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. Eur J Heart Fail 18: 28–37, 2016